Industry
Biotechnology
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Loading...
Open
3.71
Mkt cap
579M
Volume
459K
High
3.78
P/E Ratio
-12.47
52-wk high
5.02
Low
3.63
Div yield
N/A
52-wk low
1.97
Portfolio Pulse from
November 26, 2024 | 7:00 pm
Portfolio Pulse from
November 14, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 4:10 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 7:01 pm
Portfolio Pulse from Avi Kapoor
August 19, 2024 | 12:27 pm
Portfolio Pulse from Avi Kapoor
August 19, 2024 | 9:18 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 5:58 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.